Inhibiting cancer cell proliferation via targeting Cdk4/6 and other cell cycle regulators is a therapeutic strategy which appears to show much promise in the treatment of several solid tumor types, including bladder cancers [43,46,47,48]. This evidence concerns the gene CDK4 and urinary bladder cancer.